Last reviewed · How we verify

Loratadine/montelukast combination — Competitive Intelligence Brief

Loratadine/montelukast combination (Loratadine/montelukast combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihistamine and leukotriene receptor antagonist combination. Area: Immunology / Allergy / Respiratory.

phase 3 Antihistamine and leukotriene receptor antagonist combination H1 receptor and CysLT1 receptor Immunology / Allergy / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Loratadine/montelukast combination (Loratadine/montelukast combination) — Organon and Co. This combination blocks histamine H1 receptors (loratadine) and cysteinyl leukotriene receptors (montelukast) to reduce allergic and inflammatory responses in the airways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Loratadine/montelukast combination TARGET Loratadine/montelukast combination Organon and Co phase 3 Antihistamine and leukotriene receptor antagonist combination H1 receptor and CysLT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihistamine and leukotriene receptor antagonist combination class)

  1. Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Loratadine/montelukast combination — Competitive Intelligence Brief. https://druglandscape.com/ci/loratadine-montelukast-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: